Hemocellular Therapeutics establishes licensing agreement with UNC, ECU

tional hemostatic agent is known to be in this stage of development, he said, and the need for such an agent to be developed is critical, particularly in acute-care settings. Human trials could start as early as 18 months from now, he added.

The U.S. Centers for Disease Control and Prevention has reported more than 4 million admissions to non-federal hospitals nationwide in 1999 where active bleeding was the primary or secondary diagnosis. In addition, tens of thousands of deaths are estimated to occur nationwide each year due to issues related to bleeding.

"We see tremendous implications for this technology," said Basile. "Our primary focus, ultimately, is to bring doctors and other health-care professionals a new tool in dealing with the very serious medical challenges associated with clinical bleeding. We also see this as a means to strengthen our nation's biodefense efforts."

The current standard of care, liquid-stored platelets, does not provide immediate responsiveness after reinfusion, is vulnerable to viral or bacterial infection and can be stored for only five days.

The technology licensed to Hemocellular modifies human platelets to be a hemostatic agent that has a long shelf life (as long as five years), is safe and sterile, and provides immediate response to platelet-related bleeding.

"Carolina's partnership with Hemocellular represents a best-case model of how promising research discoveries can ultimately translate into solutions to some of our nation's most critical challenges," said Mark Crowell, associate vice chancellor for economic development and director of technology development at UNC. "Our state benefits tremendously, as well, with research and the company based in North Carolina, and the possibility of hundreds of new jobs when this product prepares to enter the marketplace."

From 1997 through 2002, UNC spawned 22 new spin-off companies based on faculty research. Fifteen launched in 2001-2002,

Contact: Deb Saine
University of North Carolina at Chapel Hill

Page: 1 2 3

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
4. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
5. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
6. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
7. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
8. Immerge BioTherapeutics announces identification of PERV receptor
9. Acorda Therapeutics acquires CeNeS neuregulin products
10. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
11. Genome Therapeutics, University of Southampton and Schering-Plough identify novel asthma gene

Post Your Comments:

(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... instrumentation, is pleased to announce the next event in a series of TOPIQ ... , The TOPIQ series of webinars was developed in response to social distancing ...
(Date:6/13/2020)... ... June 11, 2020 , ... ... announces a significant expansion of its forensic genealogy team. Bode’s Forensic Genealogy ... through proven forensic genealogy and DNA analysis methods. The team has added experienced ...
(Date:6/5/2020)... ... June 04, 2020 , ... Greffex, a pioneering vaccine and gene therapy ... , “Neil understands the need for a global perspective to make an impact in ... Mr. Bush will serve as an independent, director of the company. , “The Greffex ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... 2020 , ... Dracen Pharmaceuticals Inc., announced today that two ... the American Association for Cancer Research Virtual meeting. One poster describes the immuno-metabolism ... agent activity in KEAP1 mutant tumor models of NSCLC. , “As ...
(Date:6/11/2020)... ... June 09, 2020 , ... TRX ... NEON Micro-Tracer Solution, a highly accurate, contact tracing solution for identification ... workplace. Contact tracing, a core disease control measure, is a key strategy for ...
(Date:5/30/2020)... ... 29, 2020 , ... The Conference Forum is pleased to ... to the unique role of the Chief Medical Officer in the biotech industry. ... best practices and career development of CMOs and Heads of R&D from different ...
(Date:5/21/2020)... Eden Prairie, MN (PRWEB) , ... May 19, 2020 , ... ... solution to help patients get dental implants and bone grafting through PIEZOSURGERY® ... surrounding tissues. This is often used to prepare a patient for dental implants, especially ...
Breaking Biology Technology:
Cached News: